Sepsis is a life-threatening condition characterized by organ dysfunction due to a dysregulated host response to infection. One of the most common and clinically important complications of sepsis is sepsis-induced myocardial injury (SIMI), which contributes substantially to adverse outcomes. This study aimed to evaluate whether Artesunate (AS) exerts a protective effect against SIMI and to explore underlying molecular mechanisms by integrating network pharmacology predictions with experimental validation in an established animal model.
The investigators used male Wistar rats and induced sepsis via the cecal ligation and puncture (CLP) method, a widely used preclinical model of polymicrobial sepsis. Animals were randomized into five groups with n = 6 per group: Ctrl (no procedure), Sham (surgical control), CLP (sepsis), AS + CLP (Artesunate-treated sepsis), and vehicle + CLP (vehicle-treated sepsis). The randomization and group structure were intended to isolate effects of CLP-induced sepsis and to compare AS treatment against vehicle control.
To assess cardioprotective effects, the study measured established serum biomarkers of myocardial injury using ELISA. Reported analytes included brain natriuretic peptide (BNP), lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), and high-sensitivity cardiac troponin I (hs-cTnI). In addition to biochemical markers, myocardial histopathology was evaluated using hematoxylin and eosin (H&E) staining to inspect tissue-level injury and structural alterations.
The authors incorporated a network pharmacology approach to predict potential molecular targets and signaling pathways through which Artesunate might exert effects against SIMI. This computational strategy typically integrates drug–target databases, disease-associated gene sets, protein–protein interaction networks, and pathway enrichment analyses to prioritize candidate targets and mechanistic pathways for experimental follow-up. The JAK2/STAT3 signaling cascade was identified as a pathway of interest and selected for subsequent experimental validation.
Given the known contributions of systemic inflammation, oxidative stress, and cardiomyocyte apoptosis to sepsis-associated cardiac dysfunction, the study measured serum inflammatory cytokines and oxidative stress markers by ELISA. Specifically, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were quantified to evaluate the inflammatory response. Oxidative stress was assessed through superoxide dismutase (SOD) activity and malondialdehyde (MDA) levels. Cardiomyocyte apoptosis in myocardial tissue was examined using TUNEL staining to detect DNA fragmentation consistent with apoptotic cell death.
To probe the mechanistic role of the JAK2/STAT3 pathway in any observed cardioprotective effects of AS, myocardial expression of key proteins in this signaling cascade was measured by Western blotting. Western blot analysis of myocardial tissue allows assessment of total and, where applicable, phosphorylated forms of signaling proteins to infer pathway activation or inhibition.
The abstract in the source text truncates mid-sentence at the start of the Results section and does not provide specific experimental outcomes, quantitative data, statistical analyses, or the authors' final conclusions. The source confirms that the study collected biochemical, histological, inflammatory, oxidative stress, apoptotic, and signaling-protein data, and that the JAK2/STAT3 pathway was investigated as a candidate mechanism. However, the magnitude and direction of effects (for example, whether AS significantly altered cardiac biomarkers, histopathology, cytokine levels, oxidative markers, apoptosis, or JAK2/STAT3 protein expression) are not reported in the available abstract.
Based on the available content, the investigation was designed as a paired computational and experimental study to test whether Artesunate mitigates sepsis-induced myocardial injury in a CLP rat model and to assess involvement of the JAK2/STAT3 signaling pathway. The methodology included standard biochemical, histological, immunoassay, apoptosis, and Western blot endpoints appropriate for evaluating cardioprotection and mechanism. Specific results, effect sizes, and definitive conclusions were not present in the provided source material due to truncation of the abstract. For full appraisal of efficacy, statistical robustness, and translational relevance, the full text should be consulted to review complete results, figures, and authors' interpretations.